Pular para o conteúdo
Esclerodermia
ORPHA:801CID-10 · M34DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
DermatológicoInício todas idadesHerança Unknown
Também conhecida comoEsclerose SistêmicaEsclerodermaMorfeaES

A esclerodermia é uma doença autoimune rara do tecido conjuntivo caracterizada pelo endurecimento anormal da pele e, às vezes, de outros órgãos. É classificada em duas formas principais: esclerodermia localizada e esclerose sistêmica (ES), esta última compreendendo três subgrupos; ES cutânea difusa (SSc), ES cutânea limitada (SSc) e ES limitada (ESl).

Última verificação: Fonte: verificadoEm construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

A esclerodermia é uma doença autoimune rara que causa o endurecimento e a rigidez da pele e, em alguns casos, pode atingir outros órgãos internos. As pessoas afetadas costumam notar dificuldades nas mãos, feridas ou cicatrizes nas pontas dos dedos e alterações nos vasos sanguíneos ou na digestão. Não se trata de uma infecção, e a sua transmissão hereditária tradicional é classificada como não aplicável nas bases de dados. No Brasil, o SUS oferece suporte e dispensa medicamentos para controle da forma sistêmica da doença, incluindo vasodilatadores e imunossupressores descritos em protocolo oficial.

📋
Informacoes curadas por IA — podem conter imprecisoes

A esclerodermia é uma doença autoimune rara do tecido conjuntivo caracterizada pelo endurecimento anormal da pele e, às vezes, de outros órgãos. É classificada em duas formas principais: esclerodermia localizada e esclerose sistêmica (ES), esta última compreendendo três subgrupos; ES cutânea difusa (SSc), ES cutânea limitada (SSc) e ES limitada (ESl).

Pesquisas ativas
60 ensaios
308 total registrados no ClinicalTrials.gov
Publicações científicas
18.199 artigos
Último publicado: 2026 Mar

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
42.0
Worldwide
Início
All ages
🏥
SUS: Cobertura parcialScore: 30%
CID-10: M34
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧬
Pele e cabelo
19 sintomas
🫃
Digestivo
15 sintomas
🦴
Ossos e articulações
12 sintomas
💪
Músculos
8 sintomas
🫁
Pulmão
7 sintomas
❤️
Coração
7 sintomas

+ 63 sintomas em outras categorias

Características mais comuns

—
Boca estreita
—
Anormalidade no teste de função pulmonar
—
Arritmia
—
Anormalidade da morfologia dos anexos da pele
—
Anormalidade do sistema cardiovascular
—
Tireoidite de Hashimoto
157sintomas
Sem dados (157)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 157 características clínicas mais associadas, ordenadas por frequência.

Boca estreitaNarrow mouth
Anormalidade no teste de função pulmonarAbnormality on pulmonary function testing
ArritmiaArrhythmia
Anormalidade da morfologia dos anexos da peleAbnormality of skin adnexa morphology
Anormalidade do sistema cardiovascularAbnormality of the cardiovascular system

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico18.199PubMed
Últimos 10 anos200publicações
Pico2026170 papers
Linha do tempo
2026Hoje · 2026🧪 1986Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

6 genes identificados com associação a esta condição. Padrão de herança: Not applicable.

CCN2CCN family member 2Candidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
RUNX3 regulates YAP1-mediated transcriptionYAP1- and WWTR1 (TAZ)-stimulated gene expression
MECANISMO DE DOENÇA

Kyphomelic dysplasia

An autosomal recessive skeletal dysplasia characterized by bowing of the limbs primarily affecting the femora, along with short stature, short and wide iliac wings, horizontal acetabular roof, platyspondyly, metaphyseal flaring and distinctive facial features that include prominent forehead, micrognathia, microstomia, cleft palate and low set ears.

OUTRAS DOENÇAS (4)
kyphomelic dysplasiaspondyloepimetaphyseal dysplasia, Li-Shao-Li typediffuse cutaneous systemic sclerosislimited cutaneous systemic sclerosis
HGNC:2500UniProt:P29279
IRF5Interferon regulatory factor 5Candidate gene tested inTolerante
VIAS BIOLÓGICAS (3)
Interferon gamma signalingInterferon alpha/beta signalingSLC15A4:TASL-dependent IRF5 activation
MECANISMO DE DOENÇA

Inflammatory bowel disease 14

A chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
112.8 TPM
Baço
39.3 TPM
Pulmão
19.5 TPM
Rim - Medula
19.1 TPM
Sangue
18.6 TPM
OUTRAS DOENÇAS (6)
systemic lupus erythematosusprimary biliary cholangitisdiffuse cutaneous systemic sclerosislimited cutaneous systemic sclerosis
HGNC:6120UniProt:Q13568
KIAA0319LDyslexia-associated protein KIAA0319-like proteinCandidate gene tested inRestrito
EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
34.9 TPM
Tireoide
34.7 TPM
Nervo tibial
31.5 TPM
Cérebro - Hemisfério cerebelar
30.8 TPM
Cerebelo
29.9 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
systemic lupus erythematosuslimited cutaneous systemic sclerosis
HGNC:30071UniProt:Q8IZA0
CCR6C-C chemokine receptor type 6Candidate gene tested inModerado
VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsChemokine receptors bind chemokinesBeta defensins
OUTRAS DOENÇAS (2)
limited cutaneous systemic sclerosisdiffuse cutaneous systemic sclerosis
HGNC:1607UniProt:P51684
CAV1Caveolin-1Candidate gene tested inTolerante
VIAS BIOLÓGICAS (4)
SARS-CoV-2 targets host intracellular signalling and regulatory pathwaysSARS-CoV-1 targets host intracellular signalling and regulatory pathwaysExtra-nuclear estrogen signalingBasigin interactions
MECANISMO DE DOENÇA

Lipodystrophy, congenital generalized, 3

A form of congenital generalized lipodystrophy, a metabolic disorder characterized by a near complete absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and diabetes mellitus. CGL3 inheritance is autosomal recessive.

OUTRAS DOENÇAS (6)
pulmonary hypertension, primary, 3partial lipodystrophy, congenital cataracts, and neurodegeneration syndromecongenital generalized lipodystrophy type 3heritable pulmonary arterial hypertension
HGNC:1527UniProt:Q03135
HLA-DRB1HLA class II histocompatibility antigen, DRB1 beta chainCandidate gene tested inRestrito
VIAS BIOLÓGICAS (7)
Generation of second messenger moleculesTranslocation of ZAP-70 to Immunological synapsePhosphorylation of CD3 and TCR zeta chainsCo-inhibition by PD-1Downstream TCR signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1832.6 TPM
Pulmão
1234.8 TPM
Baço
990.6 TPM
Intestino delgado
607.2 TPM
Nervo tibial
598.3 TPM
OUTRAS DOENÇAS (16)
narcolepsy-cataplexy syndromefollicular lymphomaVogt-Koyanagi-Harada diseasepediatric multiple sclerosis
HGNC:4948UniProt:P01911

Variantes genéticas (ClinVar)

57 variantes patogênicas registradas no ClinVar.

🧬 CCN2: NM_001901.4(CCN2):c.779_786del (p.Pro260fs) ()
🧬 CCN2: NM_001901.4(CCN2):c.443G>A (p.Cys148Tyr) ()
🧬 CCN2: NM_001901.4(CCN2):c.65G>C (p.Arg22Pro) ()
🧬 CCN2: NC_000006.11:g.(?_131894423)_(133849943_?)del ()
🧬 CCN2: GRCh37/hg19 6q23.2-24.2(chr6:131569837-145572239)x3 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1 variantes classificadas pelo ClinVar.

1
Patogênica (100.0%)
VARIANTES MAIS SIGNIFICATIVAS
SLC39A13: NM_001128225.3(SLC39A13):c.398C>T (p.Thr133Met) [Conflicting classifications of pathogenicity]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado3
3Fase 310
2Fase 214
1Fase 16
·Pré-clínico67
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 100 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Esclerodermia

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 27 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

36 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT06991114 · AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-…Recrutando
PHASE2🇧🇷 Brasil · Bulgaria · 🇫🇷 França +8
NCT05878717 · A Study of the Efficacy and Safety of Belimumab in Adults Wi…Recrutando
PHASE2, PHASE3🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +15
NCT07470151 · Clinical Study of EVM18001 in the Treatment of Refractory Au…Recrutando
NA🇨🇳 China
NCT07256418 · Transcriptomic Study of Cutaneous Fibroblasts in SclerodermaRecrutando
🇫🇷 França
NCT07251179 · Characterization of Autoreactive b Lymphocytes in Autoimmune…Recrutando
🇫🇷 França
NCT07292961 · Investigating the Effectiveness of the Biopsychosocial Model…Recrutando
NATurkey (Türkiye)
NCT07090226 · Diffuse Cutaneous Scleroderma (DSSc) SFDI StudyRecrutando
NA🇺🇸 Estados Unidos
NCT07641634 · A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Parti…Recrutando
PHASE1, PHASE2🇦🇺 Austrália · 🇨🇳 China · 🇲🇽 México +1
NCT06599411 · Identification of Cutaneous and Blood Biomarkers Predictive …Recrutando
🇫🇷 França
NCT07343115 · Familial Systemic SclerodermaRecrutando
🇫🇷 França
NCT07183072 · Patients Diagnosed With Scleroderma: Physical Performance an…Recrutando
Turkey (Türkiye)
NCT07182981 · Patients Diagnosed With Scleroderma and Their Chewing and Sw…Recrutando
Turkey (Türkiye)
NCT07182968 · Cultural Adaptation, Validity, and Reliability of the Turkis…Recrutando
Turkey (Türkiye)
NCT06256575 · Study of Diosmin for the Treatment of Digital Ulcers in Syst…Recrutando
NA🇨🇦 Canadá
NCT06801119 · Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs)Recrutando
PHASE1🇨🇳 China
NCT06182293 · Periodontal Microbiota in Systemic SclerosisRecrutando
NA🇫🇷 França
NCT03800017 · Skeletal Muscle Function in Interstitial Lung DiseaseRecrutando
NA🇨🇦 Canadá
NCT06328777 · RESET-SSc: An Open-Label Study to Evaluate the Safety and Ef…Recrutando
PHASE2, PHASE3🇺🇸 Estados Unidos
NCT06195072 · Platform Clinical Study for Conquering SclerodermaRecrutando
PHASE2🇺🇸 Estados Unidos
NCT06339957 · Rheumatology Diet StudyRecrutando
🇺🇸 Estados Unidos
NCT06593041 · ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUSRecrutando
🇫🇷 França
NCT05098704 · Preventive Effect of Clopidogrel on the Systemic Sclerosis D…Recrutando
PHASE2, PHASE3🇫🇷 França
NCT07345052 · Western Sweden Systemic Sclerosis ProjectRecrutando
🇸🇪 Suécia
NCT05251415 · Clinico-biological Collection to Investigate the Physiopatho…Recrutando
🇫🇷 França
NCT04804930 · Trichoscopy and Systemic SclerodermaRecrutando
🇫🇷 França
NCT04797286 · Sildenafil for Early Pulmonary Vascular Disease in Scleroder…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT04265144 · Cohort of Patients With Systemic Sclerosis Within the Framew…Recrutando
NA🇫🇷 França
NCT03816345 · Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Ad…Recrutando
PHASE1🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT03276923 · Maternal Autoimmune Disease Research Alliance (MADRA) Regist…Recrutando
🇺🇸 Estados Unidos
NCT01884051 · Hormonal, Metabolic, and Signaling Interactions in PAHRecrutando
🇺🇸 Estados Unidos
NCT01776398 · Collection of Airway, Blood and/or Urine Specimens From Subj…Recrutando
🇺🇸 Estados Unidos
NCT01808937 · Morphea in Adults and Children (MAC) Cohort Study: A Morphea…Recrutando
🇺🇸 Estados Unidos
NCT01656447 · Scleroderma Registry & Repository at the Hospital for Specia…Recrutando
🇺🇸 Estados Unidos
NCT06763783 · Vaccination Against Herpes Zoster in Patients With Inflammat…Por convite
PHASE4🇸🇪 Suécia
NCT06847750 · Elastography Ultrasound in Localized Scleroderma (Morphea) S…Por convite
🇨🇦 Canadá
NCT04875078 · UVA-1 for Treatment of Skin Tightening and Improvement of Ha…Por convite
NA🇺🇸 Estados Unidos

Outros ensaios clínicos

308 ensaios clínicos encontrados, 60 ativos.

Distribuição por fase
NCT07854483 · A Phase 1b Study of C-CAR168 in Participants With Systemic S…Em breve
PHASE1
NCT07858838 · Using AI-Assisted Cameras to Track Hand Exercises in Sclerod…Em breve
NATurkey (Türkiye)
NCT07778446 · A Study to Test CRT-402 in Refractory Autoimmune DiseaseEm breve
PHASE1, PHASE2🇦🇺 Austrália
NCT07759557 · Efficacy of A Non-Invasive Botulinum Toxin Microneedle Pad f…Em breve
PHASE3
NCT07502105 · Efficacy and Safety of Firsekibart in the Treatment of Syste…Em breve
NA🇨🇳 China
NCT07326033 · Efficacy and Safety of Allogenic Cultured Adipose-derived Me…Em breve
PHASE2🇫🇷 França
NCT07186439 · Pulmonary Hypertension Screening in SclerodermaEm breve
NCT07015060 · Pathogenic Mechanisms Involved in the Initiation and Progres…Em breve
NA
NCT06776575 · Ultrasound and Electrophysiology Study of Hand in Systemic S…Em breve
NCT06264492 · Delving Into Participation Trends of Scleroderma Clinical Tr…Em breve
🇺🇸 Estados Unidos
NCT06680310 · Ultrasonic COmparison of Salivary Glands in Autoimmune Disea…Em breve
🇫🇷 França
NCT06684132 · Respiratory Muscle Training in SclerodermaEm breve
NA
NCT06655896 · Phase 2 Study Evaluating Rapcabtagene Autoleucel in Particip…Ativo
PHASE2🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +19
NCT07493395 · Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Scleros…Ativo
PHASE2🇫🇷 França
NCT07661836 · Personalized Online Occupational Therapy Intervention for Ad…Ativo
NA🇪🇸 Espanha
NCT06880627 · Brain Boost Program to Improve Cognitive Function in People …Ativo
NA🇺🇸 Estados Unidos
NCT06843239 · Tibulizumab Systemic Sclerosis Understanding and Response Ev…Ativo
PHASE2🇦🇷 Argentina · 🇨🇱 Chile · Hungary +7
NCT06697561 · Development and Evaluation of an Evidence-based Education Pr…Ativo
NA🇹🇼 Taiwan
NCT05925803 · Determine Effectiveness of Anifrolumab In SYstemic Sclerosis…Ativo
PHASE3🇦🇹 Áustria · 🇧🇪 Bélgica · 🇨🇦 Canadá +20
NCT05672992 · Longitudinal Spatial Frequency Domain Imaging StudyAtivo
NA🇺🇸 Estados Unidos
NCT05726630 · Clinical Study of Divozilimab in Patients With Systemic Scle…Ativo
PHASE3Russia
NCT04380831 · TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Trans…Ativo
EARLY_PHASE1🇺🇸 Estados Unidos
NCT04922736 · Patient Reported Outcomes With UVA-1 Therapy for Treatment o…Ativo
NA🇺🇸 Estados Unidos
NCT02682511 · Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis…Ativo
PHASE2🇮🇳 Índia · 🇺🇸 Estados Unidos
NCT05559580 · A Study in People With Systemic Sclerosis to Test Whether Av…Concluído
PHASE2🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +34
NCT02597933 · A Trial to Compare Nintedanib With Placebo for Patients With…Concluído
PHASE3🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +29
NCT02610842 · Hands on - a Hand Care Guide in Systemic SclerosisConcluído
NA🇧🇷 Brasil
NCT01347008 · Effect of Sildenafil on the Microcirculatory Blood Flow and …Concluído
PHASE3🇧🇷 Brasil
NCT00740285 · Effectiveness and Safety of Lidocaine for SclerodermaConcluído
PHASE2, PHASE3🇧🇷 Brasil
NCT06373263 · Evaluating Tools to Communicate Scleroderma Research Results…Concluído
NA🇨🇦 Canadá
NCT06999226 · RENEW-AI: Personalizing Scleroderma Management With an AI He…Concluído
NA🇺🇸 Estados Unidos
NCT06621628 · Photobiomodulation in Children With Localized SclerodermaConcluído
NA🇪🇬 Egito
NCT06772896 · Evaluating the Effect of Questionnaire Context on the Report…Concluído
NA🇨🇦 Canadá
NCT07472166 · Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutane…Concluído
PHASE4Bangladesh
NCT06646146 · Study on the Efficacy of Autologous Fat Grafting in Improvin…Concluído
NA🇨🇳 China
NCT06646913 · TENS in SclerodermaConcluído
NA🇺🇸 Estados Unidos
NCT05995626 · Hyaluronidase Via LADD Scleroderma-induced MicrostomiaConcluído
EARLY_PHASE1🇺🇸 Estados Unidos
NCT06338722 · Making it Work Program for Systemic SclerosisConcluído
NA🇺🇸 Estados Unidos
NCT06990386 · Self-management Telehealth Program for SclerodermaConcluído
NAThailand
NCT05961267 · Study of Gynecological Follow-up of Patients With Autoimmune…Concluído
🇫🇷 França
NCT06587828 · A Biospecimen Collection Study to Identify the Targets of Di…Concluído
🇺🇸 Estados Unidos
NCT05617066 · Stress, Scleroderma and Quality of LifeConcluído
NA🇪🇸 Espanha
NCT05622578 · Phenotyping of Chronic Pain in Diffused Systemic SclerodermaConcluído
NA🇫🇷 França
NCT05204355 · MRI for Screening and Monitoring Scleroderma ILDConcluído
🇺🇸 Estados Unidos
NCT06536595 · Validity and Reliability of the Turkish Version of HAnDEConcluído
Turkey (Türkiye)
NCT05171114 · Scleroderma: Functional Disability Between the Dominant and …Concluído
NA🇫🇷 França
NCT05963048 · Rituxmab Versus IL-6 in Treating ILDConcluído
PHASE2, PHASE3🇪🇬 Egito
NCT04246528 · SPIN Self-Management Feasibility Trial With Progression to F…Concluído
NA🇨🇦 Canadá
NCT05080738 · Upper Extremity Home Exercises in Patients With SclerodermaConcluído
NATurkey (Türkiye)
NCT04908943 · RENEW Scleroderma: A Peer-Mentored, Web Intervention for Res…Concluído
NA🇺🇸 Estados Unidos
NCT04647890 · Effects of FT011 in Systemic SclerosisConcluído
PHASE2🇦🇺 Austrália · 🇳🇱 Países Baixos · 🇵🇱 Polônia +2
NCT04746313 · Prevalence of Hyperprolactinemia in Systemic SclerodermaConcluído
🇫🇷 França
NCT04683029 · A Study of Guselkumab in Participants With Systemic Sclerosi…Concluído
PHASE2🇯🇵 Japão
NCT04752397 · The Influence of Extracorporeal Photopheresis on Skin Sclero…Concluído
🇩🇪 Alemanha
NCT06425653 · Exercise With Scleroderma Functional OutcomesConcluído
NATurkey (Türkiye)
NCT04532151 · Optical Coherence Tomography Imaging in Systemic SclerosisConcluído
NA🇫🇷 França
NCT04148716 · microRNAs in Systemic SclerodermaConcluído
🇫🇷 França
NCT04684225 · Telerehabilitation on Hand-Affected SclerodermaConcluído
NATurkey (Türkiye)
NCT04588714 · Feasibility and Preliminary Effects of the Resilience-based,…Concluído
NA🇺🇸 Estados Unidos
NCT04464434 · Upfront Autologous HSCT Versus Immunosuppression in Early Di…Concluído
PHASE4🇮🇹 Itália · 🇳🇱 Países Baixos · 🇬🇧 Reino Unido
NCT06095921 · The Effect of a Self-Management Program on Individuals With …Concluído
NATurkey (Türkiye)
NCT04200755 · Clinical Trial to Evaluate Efficacy and Safety of Dupilumab …Concluído
PHASE2🇩🇪 Alemanha
NCT04523506 · The Effects of Botulinum Toxin on Oral Aperture in Patients …Concluído
EARLY_PHASE1🇺🇸 Estados Unidos
NCT04335279 · Evaluation of the Scleroderma Patient-centered Intervention …Concluído
NA🇨🇦 Canadá
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
5.825 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 5.825

#1

Autologous stem cell transplant for severe, progressive juvenile systemic sclerosis.

Stem cells translational medicine2026 Mar 23

A esclerose sistêmica juvenil (jSSc) é uma doença autoimune rara e grave em crianças/adolescentes, caracterizada por endurecimento da pele, danos a órgãos e opções terapêuticas subótimas. Diante da limitação dos tratamentos convencionais, este estudo de caso relata uma melhora clínica promissora em um paciente de 17 anos com jSSc refratária após um transplante autólogo de células-tronco. Isso sugere uma potencial nova via de tratamento para casos graves e resistentes.

🇧🇷 traduzido
#2

Automatic assessment of lung involvement in systemic sclerosis using deep learning.

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2026

Este estudo utiliza inteligência artificial (deep learning) para avaliar automaticamente o envolvimento pulmonar em pacientes com esclerodermia sistêmica, aprimorando a precisão diagnóstica em tomografias e minimizando erros humanos. A tecnologia identifica e quantifica as áreas de dano pulmonar, como reticulação e opacidades em vidro fosco, oferecendo aos médicos uma medida objetiva e detalhada da extensão da doença para um acompanhamento e tratamento mais eficazes dos pacientes.

🇧🇷 traduzido
#3

Resting Oxygen Consumption Estimates in Scleroderma Can Lead to Underestimation of Cardiac Output.

Pulmonary circulation2026 Jan

Este estudo alerta que as estimativas padrão do consumo de oxigênio em repouso (rVO2), usadas para calcular a função cardíaca (débito cardíaco) em pacientes com esclerodermia, podem ser imprecisas. Para médicos e pacientes, isso significa que essas estimativas podem levar a uma subestimação do quão bem o coração está bombeando, resultando em diagnósticos errados e impactando o tratamento de problemas cardíacos. A medição direta do rVO2 é, portanto, recomendada para maior precisão diagnóstica.

🇧🇷 traduzido
#4

The Th17/Treg axis: a key to understanding and treating autoimmune disorders.

Open life sciences2026 Jan

Em doenças autoimunes como a esclerodermia, o sistema imunológico ataca o próprio corpo devido a um desequilíbrio entre as células T Th17 (promotoras de inflamação) e as Treg (reguladoras), resultando em inflamação crônica e danos aos tecidos. Compreender e restaurar este balanço é crucial, pois os níveis dessas células podem indicar a gravidade da doença e a eficácia do tratamento, servindo como um alvo terapêutico fundamental para otimizar abordagens clínicas atuais e futuras.

🇧🇷 traduzido
#5

Identification of key macrophage-related genes in systemic sclerosis-associated interstitial lung disease based on single-cell and bulk transcriptomic data.

PloS one2026

Focado na grave doença pulmonar intersticial associada à esclerose sistêmica (SSc-ILD), a principal causa de morte em pacientes com esclerose sistêmica e sem tratamentos eficazes, este estudo identificou os genes **ARG2, ELF3 e NKX2-1** como fatores-chave nos mecanismos relacionados aos macrófagos da doença. Para pacientes e médicos, esses achados são cruciais, pois destacam esses genes como potenciais alvos terapêuticos, com resultados de predição de drogas já sugerindo possíveis interações com medicamentos existentes, o que pode abrir caminho para o desenvolvimento de novas e mais eficazes opções de tratamento.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMC9.750 artigos no totalmostrando 198

2026

Autologous stem cell transplant for severe, progressive juvenile systemic sclerosis.

Stem cells translational medicine
2026

Definition, diagnosis, treatment for scleroderma primary heart involvement.

Best practice &amp; research. Clinical rheumatology
2026

A practical clinical approach to the diagnosis and management of morphea (localized scleroderma).

Best practice &amp; research. Clinical rheumatology
2026

Automatic assessment of lung involvement in systemic sclerosis using deep learning.

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences
2026

Prevalence of comorbidities and medication use in progressive systemic sclerosis in northeast Mexico.

Reumatologia clinica
2026

Implications of Dermatologic Disorders in Facial Cosmetic Surgery: A Systematic Review.

Annals of plastic surgery
2026

Circumscribed Morphea Successfully Treated With Excimer Laser: Analysis of Histopathological Changes.

The Journal of dermatology
2026

Strabismus as the Initial Manifestation of En Coup De Sabre in Adult Patients.

Neuro-ophthalmology (Aeolus Press)
2026

The immune landscape of systemic sclerosis: from pathogenic mechanisms to precision therapeutic breakthroughs.

Frontiers in immunology
2026

Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST score.

Annals of the rheumatic diseases
2026

Performance of Circulating Inflammatory Biomarkers and Krebs von den Lungen 6 for Predicting Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease.

ACR open rheumatology
2026

Nailfold capillaroscopy improves cardiovascular risk stratification in SSc: an adjustment of the SCORE2 algorithm.

Rheumatology (Oxford, England)
2026

Fibrosis-memory is mediated by IL-3-producing T cells and drives progression of fibrosis.

The Journal of clinical investigation
2026

Chronic graft versus host disease in upper limb: Calling upper limb rehabilitation specialists for improving outcomes in patients.

Clinical hematology international
2026

Optical coherence tomography angiography: a window on systemic sclerosis microangiopathy.

European journal of internal medicine
2026

Real-World Adherence to Systemic Sclerosis Quality Indicators: A Single-Center Quality of Care Study.

The Journal of rheumatology
2026

Scleroderma sine-Raynaud in children: the Fibrotic Subtype.

The Journal of rheumatology
2026

Increased incidence of sudden cardiac death in systemic sclerosis: data from a nationwide cohort study.

Seminars in arthritis and rheumatism
2026

Trends and outcomes of lung transplant listings for connective tissue disease-associated interstitial lung disease (CTD-ILD): A 20-Year analysis from the organ procurement and transplantation network database.

Seminars in arthritis and rheumatism
2026

Exploring Disease-Specific Risk Factors for Vertebral Fractures in Systemic Sclerosis: Insights from the ScleroRER Study Group.

Journal of clinical medicine
2026

Nailfold capillaroscopy and organ involvement in systemic sclerosis: a systematic review.

Best practice &amp; research. Clinical rheumatology
2026

Resting Oxygen Consumption Estimates in Scleroderma Can Lead to Underestimation of Cardiac Output.

Pulmonary circulation
2026

Analysis of fungal community structure and co-occurrence networks across vegetation types in volcanic lava habitats.

Frontiers in fungal biology
2026

Human MAGI1 expression in endothelial cells protects from the development of localized and systemic scleroderma in mice.

Arthritis research &amp; therapy
2026

Objective gastrointestinal involvement in patients with systemic sclerosis: Prevalence and clinico-immunological phenotypes in the REMSCLE registry.

Medicina clinica
2026

Dermatoscopy limitation and the critical role of capillaroscopy in the evaluation of systemic sclerosis and Raynaud's phenomenon among African American Veterans.

Seminars in arthritis and rheumatism
2026

Prevention and management of gastrointestinal side effects in patients with systemic sclerosis-interstitial lung disease receiving anti-fibrotic therapy: a modified Delphi consensus study.

Clinical and experimental rheumatology
2026

Intravenous immunoglobulin for the treatment of morphea in pediatric patients: A case series.

JAAD case reports
2026

Community-based management of gastrointestinal symptoms at end-of-life in scleroderma using subcutaneous medication: a case report.

Annals of palliative medicine
2026

The Th17/Treg axis: a key to understanding and treating autoimmune disorders.

Open life sciences
2025

A novel microneedle-based delivery of NRF2-overexpressing exosomes for scleroderma therapy.

International journal of biological macromolecules
2026

Nintedanib Attenuates Profibrotic Gene Expression in a 3D Organotypic Culture Model of Systemic Sclerosis Skin Fibrosis.

The Journal of investigative dermatology
2026

Longitudinal Assessment of the Juvenile Systemic Sclerosis Severity Score: Application in the National Registry for Childhood Onset Scleroderma.

ACR open rheumatology
2026

A retrospective analysis of clinical characteristics of systemic sclerosis-associated interstitial lung disease.

Medicine
2026

Case of generalized morphea complicated with systemic sclerosis.

Dermatology reports
2026

Exploring the anti-fibrotic effects of safflower in systemic sclerosis based on metabolomics and gut microbiota analyses.

Frontiers in pharmacology
2026

Identification of key macrophage-related genes in systemic sclerosis-associated interstitial lung disease based on single-cell and bulk transcriptomic data.

PloS one
2026

The clinical phenotype of anti-Th/To+ patients in systemic sclerosis: a case-control study within the European Scleroderma Trials and Research cohort.

Therapeutic advances in musculoskeletal disease
2026

Not all small bowel pneumatosis is ischaemia: a case-based systematic review of non-ischaemic causes.

Annals of the Royal College of Surgeons of England
2026

Recent advances in the heart and soul of primary cardiac involvement and cardiovascular disease in systemic sclerosis.

Best practice &amp; research. Clinical rheumatology
2026

Ill by mouth? Patients' experiences of the oral and dental manifestations of scleroderma.

Health (London, England : 1997)
2026

[Shulman syndrome: An atypical presentation of a rare disease].

Revista medica del Instituto Mexicano del Seguro Social
2026

Injectable platelet-rich fibrin as a valid therapeutic option for inactive linear morphea (en coup de saber): report of cases.

The Journal of dermatological treatment
2026

Generalized Morphea Successfully Treated With Tripterygium Glycosides and Hydroxychloroquine: A Case Report and a Systematic Review.

Cureus
2026

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective.

Vascular pharmacology
2026

Evaluation of non-invasive techniques for the diagnosis of pulmonary complications in systemic sclerosis and scleroderma-like overlap syndromes: role of lung ultrasound.

Journal of autoimmunity
2026

The Incidence of Painful Neuroma After Digital Amputation Due to Trauma Versus Chronic Ischemia.

Hand (New York, N.Y.)
2026

Outcomes Following Surgical Management of Advanced Oral Cavity Cancers in Patients with Scleroderma: A Case Series.

The Annals of otology, rhinology, and laryngology
2026

Reciprocal regulation of fibroblast-macrophage equilibrium governs skin integrity.

Nature immunology
2026

Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvement.

Rheumatology (Oxford, England)
2026

Successful tocilizumab-based combination therapy for a case of rapidly progressive adult deep morphea with multiple antiphospholipid antibodies: a case report and literature review.

Frontiers in immunology
2026

A university career in basic and applied avian immunology: important contributions of chicken models for autoimmune diseases.

Frontiers in physiology
2026

Computed tomography of interstitial lung disease in systemic sclerosis: dataset and deep learning model for pulmonary lesion segmentation.

Reumatismo
2026

Temporomandibular joint disorders in patients with systemic sclerosis: a cross-sectional study.

BMC rheumatology
2026

Points to consider for reporting digital ulcers in systemic sclerosis interventional studies: An initiative from the world Scleroderma Foundation digital ulcer ad hoc committee.

Autoimmunity reviews
2026

Replay: Comparative Study of Adipose-Derived Stem Cells from Localized Scleroderma Patients and Healthy Donors in Treating Skin Fibrosis.

Plastic and reconstructive surgery
2026

Extended temporomandibular joint prosthetic reconstruction of total condylysis in the setting of severe scleroderma: a case report.

Oral and maxillofacial surgery
2026

Shared governance of international myositis networks.

Clinical and experimental rheumatology
2026

Long-term follow-up of linear scleroderma en coup de sabre in children with central nervous system involvement.

Frontiers in immunology
2026

A randomised open label pilot trial comparing mycophenolate mofetil with no immunosuppression in limited cutaneous systemic sclerosis (MINIMISE-Pilot).

Rheumatology (Oxford, England)
2026

Pericardial Decompression Syndrome After Large-Volume Pericardiocentesis in Systemic Sclerosis.

JACC. Case reports
2026

Integrating B Cell Differentiation Model With Real-World Data Informs Determinants for Antibody-Secreting Cell Depletions in Systemic Sclerosis.

CPT: pharmacometrics &amp; systems pharmacology
2026

Hyaluronic acid fillers in systemic sclerosis and localized scleroderma: A systematic review.

Autoimmunity reviews
2026

Evaluating context effects on PHQ-8 somatic item scores among people with a chronic medical condition: a scleroderma patient-centred intervention network randomised experiment.

Epidemiology and psychiatric sciences
2026

Reduced retinal microvascular density in patients with mixed connective tissue disease: an exploratory pilot study on the interplay between aging, renal function, and complement system.

Frontiers in immunology
2026

Case Report: Unusual persistent elevation of troponin I-systemic sclerosis masked by acute myocardial infarction.

Frontiers in immunology
2026

Carbon dioxide vs. warm-water hand baths in systemic sclerosis with secondary Raynaud's syndrome - A capillaroscopy centered randomized controlled trial.

Microvascular research
2026

Drug development in systemic sclerosis: novel therapeutics to watch.

Expert review of clinical immunology
2026

Prevalence and clinical relevance of systematically tested antimitochondrial antibodies in systemic sclerosis.

Arthritis research &amp; therapy
2026

Cytometry-based blood immune cell markers associated with clinical outcomes in systemic sclerosis: protocol for a systematic review.

BMJ open
2026

Mechanistic basis for the antifibrotic actions of cAMP-based therapies.

European respiratory review : an official journal of the European Respiratory Society
2026

Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons.

European respiratory review : an official journal of the European Respiratory Society
2026

Assessing the structural validity of the SCL-Dep6 depression subscale using rasch analysis.

Journal of affective disorders
2026

Systemic sclerosis-associated pulmonary arterial hypertension and pulmonary fibrosis: exploring biomarker discriminators with advanced omics in a Caucasian cohort.

Frontiers in immunology
2026

An Under-Recognized Manifestation of Systemic Sclerosis: Macrovascular Peripheral Arterial Disease.

Cureus
2026

Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials.

ERJ open research
2026

A potent inhibitor of PAI-1, MDI-2517, mitigates disease severity in a preclinical systemic sclerosis model.

JCI insight
2026

Ustekinumab-associated morphoea: systematic review of the literature and a real-world case.

Drugs in context
2026

Facial Swelling in a Young Adult With Type 1 Diabetes: Morbihan Disease as a Scleroderma Mimic.

Cureus
2026

An autopsy-proven case of normotensive scleroderma renal crisis with refractory pleuroperitoneal effusion.

CEN case reports
2026

Oral and maxillofacial manifestations of systemic sclerosis.

Best practice &amp; research. Clinical rheumatology
2026

Underrecognition of Fecal Incontinence in Systemic Sclerosis: Discrepancies Between the Rome IV Diagnostic Questionnaires and the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal 2.0 Questionnaire.

The Journal of rheumatology
2026

Administration of Hormone Replacement Therapy Containing Estrogen and Development of Autoimmune Associated Vocal Fold Lesions in Women.

Journal of voice : official journal of the Voice Foundation
2026

Second to Fourth Digit Ratio (2D:4D) in Female Patients With Systemic Sclerosis: Evidence for Prenatal Androgen Exposure.

American journal of human biology : the official journal of the Human Biology Council
2026

Assessing digital vasculopathy in systemic sclerosis.

Rheumatology (Oxford, England)
2026

Advancing drug development for systemic sclerosis by prioritizing findings from human genetic association studies.

Rheumatology (Oxford, England)
2026

Exploring the optimal follow-up for systemic sclerosis patients: study protocol for a Dutch multicenter randomized controlled trial.

Trials
2026

Probabilistic Clustering Using Multivariate Growth Mixture Model in Clinical Settings-A Scleroderma Example.

Statistics in medicine
2026

Gastric disease in systemic sclerosis: Spectrum, challenges, and insights from a systematic literature review.

Seminars in arthritis and rheumatism
2026

Quantifying the Prevalence of Disorders of Gut Brain Interaction in Systemic Sclerosis.

Neurogastroenterology and motility
2026

Evaluation of serial cardiovascular magnetic resonance monitoring and immunosuppressive therapy in predicting outcomes in systemic sclerosis.

RMD open
2026

Development of enzyme-linked immunosorbent assays for the detection of myositis-specific autoantibodies against signal recognition particle, nuclear matrix protein 2, and small ubiquitin-like modifier activating enzyme.

Modern rheumatology
2026

Analysis of the Dynamics of Clinical Parameters and Serum Angiogenic Factors in Systemic Sclerosis Patients Undergoing Tocilizumab Treatment.

Experimental dermatology
2026

Age and onset timing of Raynaud's phenomenon and first non-Raynaud symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the Italian national multicenter Systemic Sclerosis Progression INvestiGation registry of the Italian Society for Rheumatology (SPRING-SIR).

Therapeutic advances in musculoskeletal disease
2026

Reactive oxygen species driven immune inflammation in systemic sclerosis: mechanisms and emerging therapeutics.

Drug discovery today
2026

Delayed gastric emptying identifies a high-risk clinical subgroup in patients with systemic sclerosis.

Rheumatology (Oxford, England)
2026

Venous Abnormalities in Biopsy-confirmed Lipodermatosclerosis.

Advances in skin &amp; wound care
2026

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.

Journal of the European Academy of Dermatology and Venereology : JEADV
2026

Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.

Annals of the rheumatic diseases
2026

Research on the mechanism of Carthamus tinctorius L. against skin fibrosis in systemic sclerosis based on serum pharmacochemistry, network pharmacology, and experimental validation.

Journal of ethnopharmacology
2026

The Spectrum of Uveitis and Retinal Vasculitis in Systemic Sclerosis: A Case Series.

Ocular immunology and inflammation
2026

Impact of Hydroxychloroquine on Mortality and Cardiovascular Outcomes in Systemic Sclerosis: A Retrospective Cohort Study.

International journal of rheumatic diseases
2026

Atypical Presentation of Morphoea in an Elderly Male: Diagnostic Challenges in the Absence of Autoantibodies and Malignancy.

Cureus
2026

Juvenile systemic sclerosis.

Best practice &amp; research. Clinical rheumatology
2026

TPI1 and TPM4 are strong candidate RNA biomarkers for systemic sclerosis.

Arthritis research &amp; therapy
2026

Spectroscopic and machine learning approaches for clinical subtyping in systemic sclerosis.

Scientific reports
2026

Comparing Novel and Legacy Health Assessment Questionnaire Scoring Methods: A Scleroderma Patient-centered Intervention Network Cohort Study.

The Journal of rheumatology
2026

Factor Analysis to Determine Subgroups of Gastrointestinal Symptoms in Systemic Sclerosis.

The Journal of rheumatology
2026

Gastrointestinal involvement in systemic sclerosis: A spotlight on small bowel involvement, complications and management.

Best practice &amp; research. Clinical rheumatology
2026

Treatment of juvenile localized scleroderma with upadacitinib: A case series.

Journal of the European Academy of Dermatology and Venereology : JEADV
2026

Th17-related genes PGAP1 and TMBIM1 serve as potential diagnostic and predictive biomarkers in systemic sclerosis: bioinformatic identification and murine model validation.

Clinical rheumatology
2026

Risk stratifying systemic sclerosis-related pulmonary hypertension by left atrial strain.

Rheumatology (Oxford, England)
2025

Fc-enhanced anti-CCR6 antibody elicits robust therapeutic effects across multiple autoimmune diseases.

Frontiers in immunology
2025

Renal Vascular Affection in Systemic Sclerosis Patients and Possible Correlation with Peripheral Vascular Involvement Assessed by Nailfold Capillaroscopy.

Mediterranean journal of rheumatology
2026

Evaluation of a screening algorithm to detect systemic sclerosis-related myopathy.

Rheumatology (Oxford, England)
2026

Methotrexate and Mycophenolate Mofetil and Clinical Response in Juvenile Localized Scleroderma.

JAMA dermatology
2026

Association of MMP9 and NOS3 Polymorphisms with Distinct Clinical Forms of Juvenile Scleroderma and Characteristics of Humoral Immunity.

International journal of molecular sciences
2026

Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Current Therapeutic Strategies and Future Prospects.

Biomolecules
2026

Serum CCL18 May Reflect Multiorgan Involvement with Poor Outcome in Systemic Sclerosis.

Biomolecules
2026

JAK inhibitors for the treatment of juvenile localized scleroderma: a case report and literature review.

Pediatric rheumatology online journal
2026

Close association of kinesiophobia with physical performance in patients with systemic sclerosis.

Rheumatology international
2025

Prevalence and severity of complicated Raynaud's phenomenon in limited and diffuse systemic sclerosis: a multicenter study in Iraq.

Reumatologia
2026

Botulinum neurotoxin type A1 alleviates bleomycin-induced skin fibrosis by inhibiting phosphatidylinositol 3-kinase-protein kinase B (PI3K-Akt) pathway and associated cell cycle and proliferation.

The Journal of investigative dermatology
2026

Gastrointestinal histology of systemic sclerosis: A systematic review.

Autoimmunity reviews
2026

Patient partnership model in rare and complex rheumatological conditions: research and beyond in European Reference Network ReCONNET.

The Lancet. Rheumatology
2026

Strengthening rheumatology research through meaningful engagement of people with lived experience.

The Lancet. Rheumatology
2026

Development of a tool to map SSc pain sources, characteristics and management experiences: the SPIN Pain Assessment Tool.

Rheumatology (Oxford, England)
2026

Linear scleroderma 'en coup de sabre'.

Practical neurology
2026

Like an Osteophyte. . . or Worse? A Curious Case of Dysphagia in a Patient With Scleroderma.

Ear, nose, &amp; throat journal
2026

Macrophages Are Critical Inducers of Bleomycin-Induced Fibrosis in a Systemic Scleroderma Model.

The American journal of pathology
2026

Surgical Management of Systemic Sclerosis: Review of Literature.

Current rheumatology reviews
2026

Forced vital capacity as a survival predictor in systemic sclerosis-associated pulmonary hypertension.

Therapeutic advances in musculoskeletal disease
2025

Esomeprazole inhibits proliferation of scleroderma fibroblasts via cell cycle regulation.

Frontiers in pharmacology
2026

Beyond the breast: Mammographic manifestations of systemic disease.

Current problems in diagnostic radiology
2026

Autoantibodies as Precision Tools in Connective Tissue Diseases: From Epiphenomenon to Endophenotype.

Antibodies (Basel, Switzerland)
2026

Differential Item Functioning on the Patient Health Questionnaire 8 by Disease Subtype, Language, Sex, and Age Among People With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study.

Arthritis care &amp; research
2026

Systemic Sclerosis-Related Intestinal Pseudo-Obstruction Mimicking Mechanical Small Bowel Obstruction.

Cureus
2026

Contemporary 0.55 T MRI to visualize interstitial lung disease - An exploratory study.

European journal of radiology open
2026

The added value of cardiac MRI in paediatric rheumatologic disorders: a preliminary single-centre experience.

Cardiology in the young
2026

The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133).

Annals of the rheumatic diseases
2026

Deficiency of inducible nitric oxide synthase alleviates dermal fibrosis and inflammation in scleroderma.

International immunopharmacology
2026

Associations with, and predictors of, progression in systemic sclerosis-related interstitial lung disease: a scoping literature review.

European respiratory review : an official journal of the European Respiratory Society
2025

MASLD-Induced Hyperammonemia With Atypical, Restricted Diffusion Pattern Suggesting Mixed Metabolic and Hypoxic-Anoxic Injury.

HCA healthcare journal of medicine
2026

Tofacitinib treatment in a girl with localized scleroderma of the head and face: a case-based review.

Rheumatology international
2026

Skin Cancer Arising in Morphea: A Systematic Review.

Journal of cutaneous medicine and surgery
2025

A Case of Mandibular Osteomyelitis Occurring in a Patient With Parry-Romberg Syndrome.

Cureus
2026

Exploring the Association Between Autoimmune and Inflammatory Diseases and Uveitis.

American journal of ophthalmology
2026

Soluble CD13 in systemic sclerosis: clinical observations and transcriptomic insights from peripheral blood.

Arthritis research &amp; therapy
2025

Temporal Dynamics of Pulmonary Fibrosis and Immune Dysregulation in a Collagen V-Driven Systemic Sclerosis Model.

International journal of molecular sciences
2026

Systemic Sclerosis-Associated ILD: Insights and Limitations of ScleroID.

Diagnostics (Basel, Switzerland)
2025

A Case Report on a Challenge From Diagnosis to Treatment: Interstitial Lung Disease As the First Manifestation of Systemic Sclerosis Sine Scleroderma.

Cureus
2026

Heart Transplantation in Patients With Systemic Sclerosis.

Clinical transplantation
2026

Clinical Applications of Autologous Fat Grafting in Pathological Hand Conditions.

The journal of hand surgery Asian-Pacific volume
2026

Disease Course and Risk of Relapse in Juvenile Localized Scleroderma: A Single-Center Retrospective Study.

International journal of rheumatic diseases
2026

Clinical predictors of mortality in critically ill systemic sclerosis patients: a 6-year retrospective cohort study.

Rheumatology (Oxford, England)
2026

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.

Nature medicine
2026

Transcriptomic analysis under the stress of insecticides and the functional role of three genes related to host finding behavior of Scleroderma sichuanensis.

Comparative biochemistry and physiology. Part D, Genomics &amp; proteomics
2026

Interstitial lung disease in systemic sclerosis-a retrospective cross-sectional study in Taiwan.

Clinical rheumatology
2026

Mesenchymal stromal cells ameliorate systemic sclerosis-interstitial lung disease via PD-1/PD-L1 signalling axis.

RMD open
2025

Combination of Oral Hydroxychloroquine and Topical Pimecrolimus 1% for Linear Morphea in Breastfeeding: A Rare Case with Favorable Outcome.

International journal of women's health
2026

Nailfold videocapillaroscopy in the assessment of juvenile connective tissue diseases.

Clinical and experimental rheumatology
2026

Deficiency of NRF2 aggravates BLM-induced systemic sclerosis-associated fibrosis and inflammation in mice.

International immunopharmacology
2026

Expression and clinical significance of fatty acid metabolism-related genes in PBMCs of SSc patients.

Clinical rheumatology
2026

Skin-derived myeloid precursors and joint-resident fibroblasts spread psoriatic disease from skin to joints.

Nature immunology
2025

Subclinical right ventricular dysfunction in juvenile systemic sclerosis: a cross-sectional echocardiographic study.

ARP rheumatology
2025

Gangrenous Digital Ischemia Unmasking HIV Infection in Untreated Systemic Sclerosis.

Cureus
2026

The Evolution in the Cutaneous and Gastrointestinal Pathology of Pediatric Kohlmeier-Degos Disease Under Combined Modality Therapy.

The American Journal of dermatopathology
2025

Parry-Romberg Syndrome Associated With En Coup De Sabre: A Clinical Case Report.

Cureus
2025

MYCOPHENOLATE MOFETIL TREATMENT REDUCES THE RISK OF TREATMENT ESCALATION DUE TO VASCULAR COMPLICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: EMULATION OF A TARGET TRIAL FROM ITALIAN RHEUMATOLOGY SOCIETY SPRING REGISTRY.

Arthritis care &amp; research
2025

Chromosomal Instability and Telomere Attrition in Systemic Sclerosis: A Historical Perspective.

Genes
2025

Autoimmune disorders as predictive factors for oral lichen planus and malignancy risk: real-world data analysis.

Oral surgery, oral medicine, oral pathology and oral radiology
2026

Hand function impairment in Systemic Sclerosis: determinants through investigations of clinical, radiographic and ultrasonographic features.

Seminars in arthritis and rheumatism
2026

Pitfalls in the treatment of keloidal scleroderma.

Internal medicine journal
2025

Antineutrophil Cytoplasmic Antibody-Associated Vasculitides in Systemic Sclerosis: A Unique Clinical Overlap With Significant Implications for Treatment and Outcomes.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2025

Single-Cell Profiling Reveals Divergent Mechanisms of Fibrosis in Localized Scleroderma and Systemic Sclerosis.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2025

Effects of multimodal nutritional intervention on nutritional status and clinical outcomes in patients with systemic sclerosis: study protocol for a randomised controlled trial.

BMJ open
2025

From the grey area of pre-systemic sclerosis to very early disease and irreversible tissue damage: the challenge of defining at-risk patients for future preventive trials in systemic sclerosis.

Annals of the rheumatic diseases
2026

Atorvastatin alleviates the progression of fibrosis in experimental systemic sclerosis: Binding to macrophage CD14 to regulate TLR4/p65 or directly modulating fibroblast Smad3 signaling.

Free radical biology &amp; medicine
2025

Systemic Sclerosis-Recent Advances in Diagnosis and Management.

British journal of hospital medicine (London, England : 2005)
2025

Systemic Sclerosis-Associated Interstitial Lung Disease: Improved Understanding and Advances in Management.

British journal of hospital medicine (London, England : 2005)
2026

Work participation and work disability in Belgian patients with systemic sclerosis.

Rheumatology (Oxford, England)
2026

Integration of natural language models in the diagnosis of systemic autoimmune diseases: validation of GPT-4 in a tertiary care center.

Revista clinica espanola
2025

The altered T cell landscape in Systemic Sclerosis patients is characterized by dysfunctional type 1 immunity.

bioRxiv : the preprint server for biology
2026

Underrepresentation of Black participants in systemic sclerosis clinical trials: the U.S.A. and southeast region.

Clinical rheumatology
2025

The efficacy and safety of tocilizumab in juvenile localised scleroderma patients: a retrospective cohort study in Eastern China.

Advances in rheumatology (London, England)
2025

Radiographic Fibrosis Extent Identifies Immunomodulatory Treatment Response in Hypersensitivity Pneumonitis.

Chest
2026

[Eosinophilic fascitis: A case report and literature review].

Revista medica del Instituto Mexicano del Seguro Social
2025

Phosphodiesterase-4 inhibition in localized scleroderma: A case series of topical roflumilast.

SAGE open medical case reports
2026

SgA1d, an acid lipase from venom of the ectoparasitoid Scleroderma guani involved in the regulation of host lipid metabolism.

Pest management science
2026

Multimodal analyses of early, untreated systemic sclerosis skin identify a proinflammatory vascular niche of macrophage-fibroblast signaling.

JCI insight
2025

Trigeminal neuropathy as the first symptom of mixed connective tissue disease: case report and literature review.

Quintessence international (Berlin, Germany : 1985)
2025

Serum profiling of uPA, PAI-1, and suPAR in systemic sclerosis: a preliminary study on analytical aspects and associations with microvascular and fibrotic manifestations.

Frontiers in immunology
2026

Gut microbiome-metabolome dysregulation in systemic sclerosis: a multi-omics study.

Rheumatology (Oxford, England)
2026

Successful Treatment of Refractory Severe Localized Scleroderma With Anifrolumab.

JAMA dermatology
2026

Hidradenitis Suppurativa and Smoking, Obesity, Psoriasis, Inflammatory Bowel Disease, and Systemic Sclerosis: Results From A 2-Sample Mendelian Randomization Study.

JAMA dermatology
2026

Automated lung texture analysis for assessing interstitial lung disease in systemic sclerosis: Diagnostic accuracy in photon-counting-detector and conventional energy-integrating-detector CT.

European journal of radiology
2025

[POEMS syndrome misdiagnosed as systemic sclerosis: A case report].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
2025

[Rheumatic disease spectrum and immunological profile of anti-PM/Scl antibodies in idiopathic inflammatory myopathies].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
Ver todos os 9.750 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Esclerodermia.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Esclerodermia e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Protocolo oficial relacionado (Ministério da Saúde)PCDT: Esclerose Sistêmica (esclerodermia)

Existe um documento oficial para "Esclerose Sistêmica (esclerodermia)". Ele pode não cobrir esta forma específica da doença — confira no texto do protocolo antes de contar com ele.

Respostas geradas por IA a partir das fontes citadas

A esclerodermia é uma doença autoimune rara caracterizada pelo espessamento e endurecimento anormal da pele e de tecidos conjuntivos. Ela pode se apresentar na forma localizada ou na forma de esclerose sistêmica, afetando órgãos internos.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

10 publicações do grafo RarasNet (PubMed) · 7 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. Automatic assessment of lung involvement in systemic sclerosis using deep learning.
    Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2026PMID 41858826
  2. ORPHA:801
    Orphanet
  3. GARD:18705
    GARD (NIH)
  4. Q958797
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Esclerodermia. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/esclerodermia

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Esclerodermia
Compêndio · Raras BR

Esclerodermia

ORPHA:801 · MONDO:0019340
Prevalência
1-5 / 10 000
Herança
Not applicable
CID-10
M34 · Esclerose sistêmica
Ensaios
60 ativos
Início
All ages
Prevalência
42.0 (Worldwide)
MedGen
UMLS
C0011644
Repurposing
2 candidatos
halofuginone — collagenase inhibitor
potassium-p-aminobenzoate
EuropePMC
Wikidata
Wikipedia
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Dado público estruturado
fonte: Wikidata
Rara